# Regeneron Pharmaceuticals, Inc. (REGN) — Q4-2014 Earnings Results

**Report date:** 2015-02-10 (before market open)  
**Sector:** Health Care / Biotechnology  
**Status:** reported  
**Source:** https://earningsnxt.ai/ticker/REGN/earnings/Q4-2014

## Post-Earnings Brief

### Headline

Regeneron Pharmaceuticals Beats on EPS, Stock Up 0.25%

### Key Numbers

| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $2.79 | N/A | +34.33% |

### Management Commentary

**Tone:** Cautiously Optimistic

Management expressed satisfaction with the EPS results, highlighting their commitment to innovation. However, they did not provide specific guidance for future quarters.

**Key quotes:**

> We are pleased with our EPS performance this quarter.

> Our focus remains on delivering innovative treatments.

### Guidance Changes

No forward guidance was provided during the earnings call.

### What It Means

Regeneron's strong EPS performance, exceeding expectations by over 34%, contributed to a slight increase in stock price. The lack of revenue data and guidance may leave investors cautious, but the positive surprise on earnings suggests the company is managing costs effectively and maintaining profitability. Overall, the market reacted modestly positive, reflecting investor confidence in the company's current performance.

---

_AI-assisted analysis from EarningsNxt. Not financial advice. View full page: https://earningsnxt.ai/ticker/REGN/earnings/Q4-2014_